notebooklm.google.com/notebook/7fc...

AI really takes education to a crazy level, I've uploaded this pdf to NotebookLM website from Google, and it generated this audio track of 2 people discussing the article 🫡

Unleashing power of AI 🤞

For oncologists based in the UK to share thoughts and discuss cancer treatment paradigm

Inspired by the other great starter packs, UK Oncologists on BlueSky starter pack is up!

Please let me know if you’d like to be added!

go.bsky.app/EfcDXY2

Starting a list of oncology related peopl. Please tell me more to add. Or any similar listd go.bsky.app/GKXp9Fy @n8pennell.bsky.social

The intriguing overall survival results of the PRIMA trial

Will this affect our treatment paradigm? 🤷‍♂️

Excellent summary of Relevant Clinical Trials With Adjuvant and Neoadjuvant Immunotherapy Components in Resectable NSCLC.

Should we adopt peri-operative approach rather than neoadjuvant pathways? 🫁

"VTE during NACTx chemotherapy for ovarian cancer"
1 in 5 patients undergoing neoadjuvant chemotherapy diagnosed with VTE.
1 in 9 diagnosed after commencing chemotherapy.
leading to delay to treatment and mortality.
Justifies the consideration of thromboprophylaxis.

Do you use Khorana score!!

ASCO updated Guideline, Version 2024.2 is now live

Published November 12, 2024

Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations.

To me, treating uncommon EGFR mutations (G719X, L861Q, S7681) is still an area of great interest.